These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 21148487)

  • 1. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
    Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
    Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.
    Tognon CE; Martin MJ; Moradian A; Trigo G; Rotblat B; Cheng SW; Pollard M; Uy E; Chow C; Carboni JM; Gottardis MM; Pollak M; Morin GB; Sorensen PH
    Oncogene; 2012 Mar; 31(10):1334-40. PubMed ID: 21804605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.
    Martin MJ; Melnyk N; Pollard M; Bowden M; Leong H; Podor TJ; Gleave M; Sorensen PH
    Mol Cell Biol; 2006 Mar; 26(5):1754-69. PubMed ID: 16478996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
    Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
    Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages.
    Lannon CL; Sorensen PH
    Semin Cancer Biol; 2005 Jun; 15(3):215-23. PubMed ID: 15826836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
    Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
    Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.
    Tognon CE; Rafn B; Cetinbas NM; Kamura T; Trigo G; Rotblat B; Okumura F; Matsumoto M; Chow C; Davare M; Pollak M; Mayor T; Sorensen PH
    J Biol Chem; 2018 Aug; 293(32):12502-12515. PubMed ID: 29903916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
    Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
    Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
    Zhang H; Pelzer AM; Kiang DT; Yee D
    Cancer Res; 2007 Jan; 67(1):391-7. PubMed ID: 17210722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation.
    Morrison KB; Tognon CE; Garnett MJ; Deal C; Sorensen PH
    Oncogene; 2002 Aug; 21(37):5684-95. PubMed ID: 12173038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
    Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
    Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
    Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
    Shukla A; Grisouard J; Ehemann V; Hermani A; Enzmann H; Mayer D
    Endocr Relat Cancer; 2009 Jun; 16(2):429-41. PubMed ID: 19153208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.
    Cui X; Kim HJ; Kuiatse I; Kim H; Brown PH; Lee AV
    Cancer Res; 2006 May; 66(10):5304-13. PubMed ID: 16707456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells.
    Riedemann J; Sohail M; Macaulay VM
    Biochem Biophys Res Commun; 2007 Apr; 355(3):700-6. PubMed ID: 17320820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway.
    Kasper G; Reule M; Tschirschmann M; Dankert N; Stout-Weider K; Lauster R; Schrock E; Mennerich D; Duda GN; Lehmann KE
    BMC Cancer; 2007 Jan; 7():12. PubMed ID: 17233884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
    Zumsteg A; Caviezel C; Pisarsky L; Strittmatter K; García-Echeverría C; Hofmann F; Christofori G
    Mol Cancer Res; 2012 Jun; 10(6):800-9. PubMed ID: 22562956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
    Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.